CSIMarket
 
60 Degrees Pharmaceuticals Inc   (NASDAQ: SXTP)
Other Ticker:  
 
 
Price: $1.8900 $0.14 8.000%
Day's High: $1.91 Week Perf: 29.45 %
Day's Low: $ 1.71 30 Day Perf: 192.8 %
Volume (M): 26 52 Wk High: $ 2.54
Volume (M$): $ 48 52 Wk Avg: $0.80
Open: $1.74 52 Wk Low: $0.08



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

60 Degrees Pharmaceuticals Inc
60 Degrees Pharmaceuticals Inc. is a pharmaceutical company focused on developing products to prevent and treat tropical diseases. They specialize in creating cost-effective solutions for conditions such as malaria, dengue fever, and other illnesses that disproportionately affect people living in tropical regions with limited access to healthcare. The company is dedicated to improving the lives of those affected by these diseases and is committed to increasing global awareness and access to effective treatments.


   Company Address: 1025 Connecticut Avenue Washington 20036 WA
   Company Phone Number: 327-5422   Stock Exchange / Ticker: NASDAQ SXTP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX        0.57% 
BHC        2.14% 
BMY   -6.5%    
REGN   -10.47%    
TEVA        11.32% 
VTRS   -4.21%    
• View Complete Report
   



Shares

60 Degrees Pharmaceuticals Initiates Reverse Stock Split to Regain Nasdaq Compliance Amidst Research Advances

Published Thu, Feb 20 2025 3:36 PM UTC

In a strategic maneuver to secure its standing on the Nasdaq exchange, 60 Degrees Pharmaceuticals (SXTP) has announced a 1-for-5 reverse stock split, scheduled to take effect on February 24, 2025. This measure will allow the company to meet Nasdaq?s $1.00 minimum bid price requirement, a crucial compliance threshold for continued listing.The reverse stock split will consolid...

Stock Market Announcement

Navigating Market Turbulence: 60 Degrees Pharmas Strategic Funding and Compliance Moves Amidst Research Breakthroughs

Published Thu, Feb 6 2025 7:08 PM UTC

In a decisive move reflecting both resilience and forward-thinking strategy in a challenging market, 60 Degrees Pharmaceuticals has successfully closed a registered direct offering totaling $1.075 million. This significant infusion of capital brings the company?s year-to-date funding total to an impressive $2.118 million. As the pharmaceutical landscape grows increasingly co...

Shares

60 Degrees Pharma Secures $1.043 Million Through Direct Offering, Elevating Total Year-to-Date Funding to $2.118 Million Amid Strategic Financial Moves,

Published Thu, Jan 30 2025 7:20 PM UTC

60 Degrees Pharma Completes $1.043 Million Registered Direct Offering: A Strategic Move to Enhance Operational FlexibilityIn a significant development for the biotechnology sector, 60 Degrees Pharma (Nasdaq: SXTP) recently announced the successful closing of a registered direct offering that raised approximately $1.043 million. The funds generated from this offering, which ...

Shares

60 Degrees Pharma Strengthens Fiscal Position Through Strategic $1.043 Million Offering, Paving Way for Future Growth,

Published Wed, Jan 29 2025 1:00 PM UTC

In a strategic move to bolster its financial foundation and support its corporate initiatives, 60 Degrees Pharmaceuticals Inc. (Nasdaq: SXTP) recently announced the culmination of a $1.043 million registered direct offering priced at-the-market under Nasdaq rules. This offering, emblematic of the company s proactive financial strategy, involved issuing common stock and warra...

Product Service News

Exploring Tafenoquine and Babesia spp 60 Degrees Pharmaceuticals Advances Research in Persistent Babesiosis and Chron...

Published Wed, Jan 8 2025 1:05 PM UTC

In a groundbreaking initiative set to enhance the treatment landscape for persistent babesiosis, 60 Degrees Pharmaceuticals has announced the enrollment of its first patient in a clinical study evaluating tafenoquine. This investigational oral medication, historically utilized for malaria prophylaxis and treatment, is now being studied for its potential to address persistent...







60 Degrees Pharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com